

Xiaoyan Chu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10223589/publications.pdf>

Version: 2024-02-01

19
papers

3,802
citations

567281

15
h-index

794594

19
g-index

19
all docs

19
docs citations

19
times ranked

4145
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1315-1323.	4.7	16
2	New and Emerging Research on Solute Carrier and ATP Binding Cassette Transporters in Drug Discovery and Development: Outlook From the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 540-561.	4.7	16
3	Clinical Implications of Altered Drug Transporter Abundance/Function and $\langle \text{sc} \rangle \text{PBPK} \langle / \text{sc} \rangle$ Modeling in Specific Populations: An $\langle \text{sc} \rangle \text{ITC} \langle / \text{sc} \rangle$ Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 501-526.	4.7	21
4	Clinical Relevance of Hepatic and Renal $\text{P-gp} \langle / \text{sc} \rangle \text{BCRP} \langle / \text{sc} \rangle$ Inhibition of Drugs: An International Transporter Consortium Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 573-592.	4.7	15
5	Coproporphyrin I as an Endogenous Biomarker to Detect Reduced $\langle \text{sc} \rangle \text{OATP1B} \langle / \text{sc} \rangle$ Activity and Shift in Elimination Route in Chronic Kidney Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 615-626.	4.7	9
6	A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 403-415.	4.7	31
7	Prediction of Transporter-Mediated Rosuvastatin Hepatic Uptake Clearance and Drug Interaction in Humans Using Proteomics-Informed REF Approach. <i>Drug Metabolism and Disposition</i> , 2021, 49, 159-168.	3.3	24
8	Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1082-1115.	4.7	88
9	Positron Emission Tomography Imaging of [¹¹ C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1056-1066.	4.7	51
10	A Comparison of Total and Plasma Membrane Abundance of Transporters in Suspended, Plated, Sandwich-Cultured Human Hepatocytes Versus Human Liver Tissue Using Quantitative Targeted Proteomics and Cell Surface Biotinylation. <i>Drug Metabolism and Disposition</i> , 2019, 47, 350-357.	3.3	37
11	Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS Proteomics. <i>Drug Metabolism and Disposition</i> , 2018, 46, 189-196.	3.3	43
12	Dabigatran Etexilate and Digoxin: Comparison as Clinical Probe Substrates for Evaluation of P-gp Inhibition. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 788-792.	4.7	32
13	Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 836-864.	4.7	141
14	Advancing Predictions of Tissue and Intracellular Drug Concentrations Using <i>In Vitro</i> , Imaging and Physiologically Based Pharmacokinetic Modeling Approaches. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 865-889.	4.7	92
15	Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative Proteomics. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1752-1758.	3.3	100
16	Generation and Characterization of a Breast Cancer Resistance Protein Humanized Mouse Model. <i>Molecular Pharmacology</i> , 2016, 89, 492-504.	2.3	23
17	Variability in P-Glycoprotein Inhibitory Potency (IC_{50}) Using Various <i>In Vitro</i> Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1347-1366.	3.3	136
18	Application of Receiver Operating Characteristic Analysis to Refine the Prediction of Potential Digoxin Drug Interactions. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1367-1374.	3.3	41

#	ARTICLE	IF	CITATIONS
19	Membrane transporters in drug development. Nature Reviews Drug Discovery, 2010, 9, 215-236.	46.4	2,886